Fig. 5: Complement lectin pathway contributes to hematopoietic and immune-regulatory roles of Pinch1/2.

A Venn diagram of dysregulated factors related to infectious diseases in the bone marrow supernatant of dKO mice. B Venn diagram of dysregulated factors in the bone marrow supernatant of dKO mice (infectious disease or immune disease). C Heatmap of dysregulated factors in the complement and coagulation cascades identified through MS in the bone marrow supernatant from control mice and dKO mice. The level of Mbl2 in bone marrow supernatant (D) or serum (E) from control mice and dKO mice (n = 8). The level of Complement component 5 in bone marrow supernatant (F) or serum (G) from control mice and dKO mice (n = 8). H, I qPCR analysis of some dysregulated factors in the complement and coagulation cascades identified through MS in the bone marrow supernatant from control mice and dKO mice (n = 8). J Representative images of H&E staining, TUNEL staining, and IF staining of F4/80 and α-SMA. Quantification of TUNEL⁺ cells (K), F4/80⁺ cells (L) and α-SMA⁺ cells (M) in the liver (n = 6). Data are mean ± SD of 3 independent experiments. N, O Representative protein expression level (n = 8 in total) and quantification of Mbl2 in the liver (n = 8 in total). Data are mean ± SD of 3 independent experiments. P, Q Representative protein expression level (n = 6 in total) and quantification of Mbl2 in primary hepatocytes co-cultured with BMSC or BMSC^dKO. Data are mean ± SD of 3 independent experiments. R The level of Cxcl12 in serum from control mice and dKO mice (n = 6). S, T Representative protein expression level and quantification of Mbl2 in primary hepatocytes stimulated with Cxcl12 for 24 h (n = 4). Data are mean ± SD of 3 independent experiments. U A schematic diagram illustrating the experimental design of rm-Mbl2 administration. V Survival curves of mice after treatment rm-Mbl2 (dissolved in normal saline, n = 12). *P < 0.05; **P < 0.01; ***P < 0.001.